scholarly journals Engineered mRNA and the Rise of Next-Generation Antibodies

Antibodies ◽  
2021 ◽  
Vol 10 (4) ◽  
pp. 37
Author(s):  
Laura Sanz ◽  
Luis Álvarez-Vallina
Keyword(s):  
Gene Delivery ◽  
Large Scale ◽  
Lead Times ◽  
Scale Production ◽  
Therapeutic Antibodies ◽  
Next Generation ◽  
Large Scale Production ◽  
Synthetic Mrna ◽  
Manufacturing Problems

Monoclonal antibodies are widely used as therapeutic agents in medicine. However, clinical-grade proteins require sophisticated technologies and are extremely expensive to produce, resulting in long lead times and high costs. The use of gene transfer methods for in vivo secretion of therapeutic antibodies could circumvent problems related to large-scale production and purification and offer additional benefits by achieving sustained concentrations of therapeutic antibodies, which is particularly relevant to short-lived antibody fragments and next-generation, Fc-free, multispecific antibodies. In recent years, the use of engineered mRNA-based gene delivery has significantly increased in different therapeutic areas because of the advantages it possesses over traditional gene delivery platforms. The application of synthetic mRNA will allow for the avoidance of manufacturing problems associated with recombinant proteins and could be instrumental in consolidating regulatory approvals for next-generation therapeutic antibodies.

Liposomes

2017 ◽  
pp. 52-87
Author(s):  
Mangal Shailesh Nagarsenker ◽  
Megha Sunil Marwah
Keyword(s):  
Quality Control ◽  
Large Scale ◽  
Clinical Success ◽  
Scale Production ◽  
Large Scale Production ◽  
Diagnostic Applications ◽  
Set Up ◽  
Insight Into ◽  
Characterisation Techniques

The science of liposomes has expanded in ambit from bench to clinic through industrial production in thirty years since the naissance of the concept. This chapter makes an attempt to bring to light the impregnable contributions of great researchers in the field of liposomology that has witnessed clinical success in the recent times. The journey which began in 1965 with the observations of Bangham and further advances made en route (targeting/stealthing of liposomes) along with alternative and potential liposome forming amphiphiles has been highlighted in this chapter. The authors have also summarised the conventional and novel industrially feasible methods used to formulate liposomes in addition to characterisation techniques which have been used to set up quality control standards for large scale production. Besides, the authors have provided with an overview of primary therapeutic and diagnostic applications and a brief insight into the in vivo behaviour of liposomes.

scholarly journals Production of Phytotoxic Metabolite Using Biphasic Fermentation System from Strain C1136 of Lasiodiplodia pseudotheobromae, a Potential Bioherbicidal Agent

2017 ◽  
Vol 9 (3) ◽  
pp. 371-377
Author(s):  
Charles Oluwaseun ADETUNJI ◽  
Julius Kola OLOKE ◽  
Gandham PRASAD ◽  
Moses ABALAKA ◽  
Emenike Onyebum IROKANULO
Keyword(s):  
Large Scale ◽  
Wild Strain ◽  
Fermentation Medium ◽  
Scale Production ◽  
Conventional Farming ◽  
Large Scale Production ◽  
Phytotoxic Metabolite ◽  
Biphasic Fermentation

Formulation of effective and environmental friendly bioherbicides depends on the type of fermentation medium used for the production of phytotoxic metabolites. The effect of biomass, colony forming unit and the phytotoxic metabolite produced from the biphasic fermentation was carried out, while the phytotoxic metabolite was  tested in vivo and in-vitro on Echinochola crus-galli and dicotyledonous Chromolaena odorata. The mutant strain of Lasiodiplodia pseudotheobromae C1136 (Lp90) produced the highest amount of conidia and the largest necrotic area on the two tested weeds when compared to its wild strain in the different biphasic media combinations. The study revealed that the biphasic system containing PDB + rice produced the highest bioherbicidal activities. Therefore, the phytotoxic metabolites from strain C1136 are suggested for large scale production of bioherbicides for the management of weeds in conventional farming to improve yield and enhance food security.

scholarly journals Nanomedicine for Gene Delivery for the Treatment of Cardiovascular Diseases

2019 ◽  
Vol 19 (1) ◽  
pp. 20-30 ◽  
Author(s):  
Cen Yan ◽  
Xiao-Jiang Quan ◽  
Ying-Mei Feng
Keyword(s):  
Gene Transfer ◽  
Gene Delivery ◽  
Dna Sequences ◽  
Large Scale ◽  
Heart Function ◽  
Current Status ◽  
Future Perspective ◽  
Scale Production ◽  
Large Scale Production ◽  
Target Molecules

Background: Myocardial infarction (MI) is the most severe ischemic heart disease and directly leads to heart failure till death. Target molecules have been identified in the event of MI including increasing angiogenesis, promoting cardiomyocyte survival, improving heart function and restraining inflammation and myocyte activation and subsequent fibrosis. All of which are substantial in cardiomyocyte protection and preservation of cardiac function. Methodology: To modulate target molecule expression, virus and non-virus-mediated gene transfer have been investigated. Despite successful in animal models of MI, virus-mediated gene transfer is hampered by poor targeting efficiency, low packaging capacity for large DNA sequences, immunogenicity induced by virus and random integration into the human genome. Discussion: Nanoparticles could be synthesized and equipped on purpose for large-scale production. They are relatively small in size and do not incorporate into the genome. They could carry DNA and drug within the same transfer. All of these properties make them an alternative strategy for gene transfer. In the review, we first introduce the pathological progression of MI. After concise discussion on the current status of virus-mediated gene therapy in treating MI, we overview the history and development of nanoparticle-based gene delivery system. We point out the limitations and future perspective in the field of nanoparticle vehicle. Conclusion: Ultimately, we hope that this review could help to better understand how far we are with nanoparticle-facilitated gene transfer strategy and what obstacles we need to solve for utilization of nanomedicine in the treatment of MI.

Construction and Expression of Mouse-human Chimeric Antibody SZ-51 Specific for Activated Platelet P-selectin

1997 ◽  
Vol 77 (04) ◽  
pp. 755-759 ◽  
Author(s):  
Jianming Gu ◽  
Yue Liu ◽  
Lijun Xia ◽  
Haiying Wan ◽  
Peixia Li ◽  
...  
Keyword(s):  
Large Scale ◽  
Variable Region ◽  
Expression Vectors ◽  
Chimeric Antibody ◽  
Scale Production ◽  
Fab Fragment ◽  
Variable Regions ◽  
E Coli ◽  
Large Scale Production

SummaryA murine monoclonal (mAb) SZ-51 specific for human P-selectin may be used for in vivo thrombus imaging and for the targeting of fibrinolytic agents to thrombi. In order to reduce the immunogenicity of the murine mAb SZ-51 in humans, we cloned and sequenced the cDNAs encoding the variable region of mAb SZ-51 in order to develop mouse/human chimeric reagents. The E. coli expression vector. pHENl-SZ51 Fab/Hu was constructed by fusing the variable regions of mAb SZ-51 with human IgG γICHI and Cκ genes. The constructs were introduced into E. coli HB2151 for expression of soluble chimeric Fab fragment. We also constructed two fusion products by joining the variable regions of mouse antibody to the appropriate constant regions of human Igγl and κ. These chimeras were cloned into two eukaryotic selectable expression vectors separately, which were then cotransfected into a non-Ig secreting murine myeloma line SP2/0 with lipofectin reagent. Six cell lines remained positive for Ig secretion. The highest producing cell line, which showed stable integration and expression at 5 mg/1 of culture, was selected for the large scale production of chimeric antibody. Immunoblotting analysis demonstrated that both of the chimeric antibodies (SZ51Fab/Hu, SZ51/Hu) in the culture supernatants, like the native mAb SZ-51, bind P-selectin. In addition, the whole chimeric antibody can compete for binding to activated platelets with murine SZ-51. Therefore, the SZ-51 chimeric antibody may be a potential agent for diagnosis and treatment of thrombotic diseases in the future.

[32] Large-scale production of retroviral vectors for systemic gene delivery

2002 ◽  
pp. 562-573 ◽  
Author(s):  
Matthew J. Huentelman ◽  
Phyllis Y. Reaves ◽  
Michael J. Katovich ◽  
Mohan K. Raizada
Keyword(s):  
Gene Delivery ◽  
Large Scale ◽  
Retroviral Vectors ◽  
Scale Production ◽  
Large Scale Production ◽  
Systemic Gene Delivery

scholarly journals Biochemical assessment of in vitro and in vivo culture of Tylophora indica (Burm. F.) Merr

1970 ◽  
Vol 6 (2) ◽  
pp. 1-5
Author(s):  
Antaryami Kaushik ◽  
Chandra Gurnani ◽  
Shyam Sunder ◽  
Abha Dhingra ◽  
Vikram Chimpa
Keyword(s):  
Large Scale ◽  
Basal Medium ◽  
Nodal Segments ◽  
Scale Production ◽  
Tylophora Indica ◽  
Shoot Initiation ◽  
Large Scale Production ◽  
Chlorophyll Protein

Tylophora indica (Burm. F.) Merr is an endangered plant which can be protected from extinction by its large scale production. Nodal segments of healthy plants are used as explants and cultured on MS Basal medium fortified with different growth regulators. Optimum shoot induction conditions from explants were established. In vitro and in vivo phytochemical test were done by using standard methods for chlorophyll, carbohydrates, proteins, lipids and starch. 3mg/l 2, 4 D showed maximum and success full callus production. Shoot initiation started in 7 days and best shoot regeneration reported with 3 mg/ml BAP in Basal medium. Combination of IBA and NAA in concentration 2 and 4 mg/l respectively proved to be best for root initiation. Concentration of chlorophyll, protein, lipid, carbohydrate, and starch in vitro and in vivo culture are investigated. DOI: 10.3126/kuset.v6i2.4005Kathmandu University Journal of Science, Engineering and Technology Vol.6. No II, November, 2010, pp.1-5

scholarly journals System for large scale production of small RNAs through their in vivo expression within 5S rRNA‐derived scaffold.

2009 ◽  
Vol 23 (S1) ◽  
Author(s):  
Yamei Liu ◽  
Victor Stepanov ◽  
Prasenjit Dey ◽  
George W. Jackson ◽  
Richard C. Willson ◽  
...  
Keyword(s):  
Small Rnas ◽  
Large Scale ◽  
5S Rrna ◽  
Scale Production ◽  
Large Scale Production ◽  
In Vivo Expression
Sign in / Sign up

Export Citation Format

Share Document